Updates are available Correction dated 2020-09-17
Click to view Correction: https://doi.org/10.1038/s41467-020-18719-8
-
Authors
Buqué, Aitziber https://orcid.org/0000-0002-7698-8778
Bloy, Norma
Perez-Lanzón, Maria
Iribarren, Kristina
Humeau, Juliette
Pol, Jonathan G.
Levesque, Sarah
Mondragon, Laura
Yamazaki, Takahiro https://orcid.org/0000-0002-7420-4394
Sato, Ai https://orcid.org/0000-0002-5408-2596
Aranda, Fernando https://orcid.org/0000-0002-9364-474X
Durand, Sylvère
Boissonnas, Alexandre
Fucikova, Jitka
Senovilla, Laura
Enot, David
Hensler, Michal
Kremer, Margerie
Stoll, Gautier https://orcid.org/0000-0002-0862-4139
Hu, Yang https://orcid.org/0000-0002-6348-874X
Massa, Chiara
Formenti, Silvia C. https://orcid.org/0000-0002-8227-8924
Seliger, Barbara
Elemento, Olivier
Spisek, Radek
André, Fabrice https://orcid.org/0000-0001-5795-8357
Zitvogel, Laurence
Delaloge, Suzette https://orcid.org/0000-0003-2106-9165
Kroemer, Guido https://orcid.org/0000-0002-9334-4405
Galluzzi, Lorenzo https://orcid.org/0000-0003-2257-8500
-
Funding
Funding for this research was provided by:
U.S. Department of Defense (BC180476P1)
- License Information
-
More Information
Article History
Received: 13 July 2019
Accepted: 10 July 2020
First Online: 30 July 2020
Change Date: 17 September 2020
Change Type: Correction
Change Details: An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Competing interests
: S.C.F. reports funding for clinical trials from Bristol Myers Squibb, Merck and Varian, and speaker and/or advisory honoraria from Astra Zeneca, Bayer, Bristol Myers Squibb, Eisai, Elekta, EMD Serono/Merck, GlaxoSmithKline, Janssen, MedImmune, Merck US, Regeneron, Varian, and ViewRay. O.E. reports research funding from Eli Lilly, Janssen, Sanofi, equities/co-founder role in Volastra Therapeutics and OneThree Biotech, and equities/advisory role in Owkin, Freenome, Genetic Intelligence and Acuamark DX. F. André reports research funding and speaker/advisory honoraria from Roche, AstraZeneca, Daiichi Sankyo, Pfizer, Novartis, and Eli Lilly. L.Z. reports research funding from Bristol Myers Squibb, Roche, Glaxo Smyth Kline, Lytix Pharma, Incyte, Merus, Tusk and Pileje (completed), and from Innovate Pharma, Kaleido, Transgene, Elior, Carrefour (ongoing), consulting/advisory honoraria from Transgene, EpiVax, Lytix Biopharma, and co-founder role in everImmune. S.D. reports funding for clinical trials from AstraZeneca, Roche, Bristol Myers Squibb, Pfizer, Novartis, Amgen, Sanofi, GE Healthcare, Merck Sharp & Dohme, Eli Lilly, Puma, Myriad, Orion, Genomic Health, Pierre Fabre and Servier, non-financial support from AstraZeneca, Roche and Pfizer. G.K. reports research funding from Bayer Healthcare, Genentech, Glaxo Smyth Kline, Institut Mérieux, Lytix Pharma, PharmaMar, Sotio and Vasculox, consulting/advisory honoraria from Bristol Myers Squibb Foundation France, co-founder role of everImmune, Samsara therapeutics and Therafast Bio. L.G. reports research funding from Lytix, and Phosplatin (completed), consulting/advisory honoraria from Boehringer Ingelheim, AstraZeneca, OmniSEQ, The Longevity Labs, Inzen, and the Luke Heller TECPR2 Foundation. All other authors have no conflicts of interest to declare.
